Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Saved in:
| Title: | Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia. |
|---|---|
| Authors: | Yang, Tingting1,2,3 (AUTHOR) 21818093@zju.edu.cn, Dong, Yetian1,2,3 (AUTHOR) 937152718@qq.com, Zhang, Mingming1,2,3 (AUTHOR) mingmingzhang@zju.edu.cn, Feng, Jingjing1,2,3 (AUTHOR) elinafengjj@foxmail.com, Fu, Shan1,2,3 (AUTHOR) fushan@zju.edu.cn, Xiao, Pingnan1,2,3 (AUTHOR) pingnanxiao@126.com, Hong, Ruimin1,2,3 (AUTHOR) hongrm0327@163.com, Xu, Huijun1,2,3 (AUTHOR) xuhuijunha@foxmail.com, Cui, Jiazhen1,2,3 (AUTHOR) cuijiazhen2008@126.com, Huang, Simao1,2,3 (AUTHOR) huangsimao2022@163.com, Wei, Guoqing1,2,3 (AUTHOR) weiguoqing2000@sina.com, Kong, Delin1,2,3 (AUTHOR) Kongdl@zju.edu.cn, Geng, Jia4 (AUTHOR) gj_1217@163.com, Chang, Alex H.5,6 (AUTHOR) changah@yakebiotech.com, Huang, He1,2,3 (AUTHOR) huanghe@zju.edu.cn, Hu, Yongxian1,2,3 (AUTHOR) 1313016@zju.edu.cn |
| Source: | Experimental Hematology & Oncology. 1/3/2025, Vol. 14 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
